Trial
NCT04002622
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Intervention
TQB2450
Why stopped
The population of target indication is small and screening is difficult.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-25